• 🎄 Home
  • Activity



    REGULATORY AFFAIRS from The Pharmaceutical Marketing Group is a regular email newsletter about regulatory affairs.

    Direct to your inbox

    Stay up to date with the latest appointments by subscribing to REGULATORY AFFAIRS! from The Pharmaceutical Marketing Group

    View the newsletter archive

    Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer

    BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ: CLVS) announced today...

    TransEnterix Announces Submission of 510(k) to FDA for First Machine Vision System in Robotic Surgery

    RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE American: TRXC),...

    Imago Receives Fast Track Designation from U.S. FDA for Bomedemstat for Treatment of Essential Thrombocythemia

    SAN FRANCISCO--(BUSINESS WIRE)--Imago BioSciences, Inc., a clinical-stage biotechnology company...

    Meissa Vaccines Receives U.S. FDA Fast Track Designation for Respiratory Syncytial Virus Vaccine, MV-012-968

    SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Meissa Vaccines (“Meissa”), a biotechnology...

    FDA Grants Breakthrough Device Designation to Reflow Medical’s Temporary Spur Stent System

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Reflow Medical announces that the Temporary...

    Penumbra Announces FDA Clearance of Indigo® Aspiration System for Treatment of Pulmonary Embolism

    ALAMEDA, Calif.--(BUSINESS WIRE)--Penumbra, Inc. (NYSE: PEN), a global healthcare...

    Newron Announces Initiation of New Clinical Trial With Evenamide in Patients With Schizophrenia, Following Approval of Plan By FDA

    MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX:...